CYTOMX THERAPEUTICSCS INC
CYTOMX THERAPEUTICSCS INC
Aktie · US23284F1057 · CTMX · A14158 (XNAS)
Übersicht Finanzkennzahlen
2,80 USD
-5,41 % -0,16 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
13.06.2025 23:57

Aktuelle Kurse von CYTOMX THERAPEUTICSCS INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
CTMX
USD
13.06.2025 23:57
2,80 USD
2,99 USD
-6,35 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 5,66 % 16,67 % 373,93 % 154,55 % 91,78 % -64,82 %

Firmenprofil zu CYTOMX THERAPEUTICSCS INC Aktie

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Investierte Fonds

Folgende Fonds haben in investiert: CYTOMX THERAPEUTICSCS INC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
11,17
Anteil (%)
0,03 %

Unternehmensdaten

Name CYTOMX THERAPEUTICSCS INC
Firma CytomX Therapeutics, Inc.
Symbol CTMX
Website https://www.cytomx.com
Heimatbörse XNAS NASDAQ
WKN A14158
ISIN US23284F1057
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Sean A. McCarthy DPHIL
Marktkapitalisierung 51 Mio
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,1 T
Adresse 151 Oyster Point Boulevard, 94080 South San Francisco
IPO Datum 2015-10-08

Ticker Symbole

Name Symbol
Frankfurt 6C1.F
NASDAQ CTMX

Weitere Aktien

Investoren die CYTOMX THERAPEUTICSCS INC die halten, haben auch folgende Aktien im Depot:
ABBVIE 19/21 REGS
ABBVIE 19/21 REGS Anleihe
AMGEN INC
AMGEN INC Aktie
ANALOG DEVICES INC
ANALOG DEVICES INC Aktie
AUTODESK INC
AUTODESK INC Aktie
BANKWELL FINANCIAL GROUP INC
BANKWELL FINANCIAL GROUP INC Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COPART INC
COPART INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
FIRSTTRUSTFACTORFX UCITS CLASSB
FIRSTTRUSTFACTORFX UCITS CLASSB ETF
GS FDS-G.S.EUR.CO.EQ.R EO
GS FDS-G.S.EUR.CO.EQ.R EO Fonds
ILLUMINA INC
ILLUMINA INC Aktie
INTEL CORP
INTEL CORP Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025